Correspondingly, we observed an increase of various PD-L1+ cell populations in RRMS patients, collectively supporting the notion that the PD-1/PD-L1 axis presents an immune checkpoint relevant in MS pathogenesis regulated in a cell-type-specific manner.46-48. This evidence concerns the gene PDCD1 and myeloid sarcoma.